Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Therapy for heparin-induced thrombocytopenia (HIT) targeting the epitope structure of the disease –inducing antibody

Description:

Technology Overview: 

Roughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis and thrombocytopenia.

 

The Greene lab has identified and compared two antibodies respectively named KKO and RTO. KKO recognizes PF4 and stabilizes the complex with heparin, a critical initiating step in the pathogenesis of HIT. Conversely, RTO binds to an epitope that overlaps with KKO on the surface of PF4, preventing PF4 tetramerization, a critical step for the pathogenesis of HIT. This knowledge of KKO and RTO will support the development of an antibody assay to diagnose and/or monitor the progression of HIT but also the development of non-anticoagulant treatment. 

 

 

Advantages: 

  • Knowledge of the first crystal structure of PF4 in a complex with Fabs
  • Provides  novel target epitope for diagnosing and the development of non-anticoagulant therapeutics for HIT
  • Potential to decrease misdiagnoses, decrease rates of complications, and decrease mortality  

 

State of Development:  

  • Solved crystal structure of PF4 in complex with antibodies
  • In vivo data showing RTO prevent HIT induced by KKO

Intellectual Property: 

 

Reference Media: 

Cai, Z. et al.; Autoimmun Rev 2016 15(7)752.

 

Desired Partnerships: 

 Collaboration

 

Docket # 14-7144 

 

 

 

Download PDF 

 

Keywords: Life Science, thrombocytopenia, diagnostic, therapeutic, antibody


Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
215-746-4275
martinv@upenn.edu
Inventors:
Mark Greene
Keywords:
Antibody